Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In AML AML for November/December 2020 Beat AML: Precision medicine strategy feasible, superior to SOC for AML, More must reads AML for September/October 2020 Survey quantifies COVID-19’s impact on oncology, More must readsAML for May/June 2020 Combo drug improves survival in older patients with high-risk/secondary AML, Venetoclax plus LDAC tops LDAC alone in AML, Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML, First-in-kind anti-CD47 antibody shows promise for MDS and AML treatment, VIALE-A confirms survival benefit for venetoclax-azacitidine in hard-to-treat AML, More must readsAML for March/April 2020 CLAM trial regimen shown safe, effective for r/r AML, Monocytic AML subclones can cause resistance to venetoclax, Monensin shows promise as a molecular scaffold for inhibiting AML, TRIM31 promotes AML progression, resistance to daunorubicin, Outpatient induction therapy for AML found feasible, More must readsAML for January/February 2020 Initial FLAG-Ida outperforms 7+3 for high-risk AML, Survival for older AML patients better with HSCT from unrelated donors, Genomic profiling of AML and MDS yields prognostic clues, More must readsPages1 2 3 4 5 6 7 last »
